<DOC>
	<DOC>NCT01513694</DOC>
	<brief_summary>The purpose of this trial is to test the effectiveness of the use of a new therapeutic strategy in treating patients with degenerative disc disease lumbar intervertebral fusion with instrumented posterolateral autologous mesenchymal stem cells and arranged in a calcium phosphate ceramic (Conduit TM).</brief_summary>
	<brief_title>Clinical Trial Based on the Use of Mesenchymal Stem Cells From Autologous Bone Marrow in Patients With Lumbar Intervertebral Degenerative Disc Disease</brief_title>
	<detailed_description />
	<mesh_term>Spinal Diseases</mesh_term>
	<mesh_term>Intervertebral Disc Degeneration</mesh_term>
	<mesh_term>Intervertebral Disc Displacement</mesh_term>
	<criteria>Clinical Box symptomatic (back pain and / or root) of lumbar degenerative disc disease monosegmental. Discopathy refractory to conservative treatment (drugs, physical therapy.) Evolution greater than or equal to 6 months. Radiological Discopathy radiation. Disc space narrowing, osteophytes, abnormal mobility, etc NMR: grades IV and V of Pfirman. Rejection of surgical treatment. Systemic inflammatory disease (spondylitis, rheumatoid arthritis etc), tumor or infection. Immunosuppressive treatment. Congenital or acquired anatomical abnormality that prevents the surgical procedure. Neuropsychiatric pathology, drug addiction, psychosis, severe personality disorder. High surgical risk (ASA&gt; IV), or contraindication to anesthesia.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Mesenchymal Stem Cells</keyword>
	<keyword>Stem Cells</keyword>
	<keyword>Intervertebral disc disease</keyword>
</DOC>